Kronik hepatit B enfeksiyonunda timozin 1 alfa ve lamivudin kombinasyonu; 3 vakalık klinik deneyim
Yükleniyor...
Tarih
2003
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Türkiye Klinikleri
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Amaç:Son zamanlarda literatürde kronik hepatit B (KHB) enfeksiyonu tedavisinde farklı ajanlarla yapılacak kombinasyonlarının etkisinin araştırılması önerilmektedir. Bugün için KHB enfeksiyonunda en iyi tedavi modeli bilinmemektedir. Materyal ve Metot: Bu amaçla daha önce kronik hepatit B tanısı alarak interferon alfa tedavisi uygulanan ve yanıt alınamayan 3 hastada eş zamanlı başlanan timozin 1 alfa (0.9 mg/m2 haftada 2 gün sc) ve lamivudin (4 mg/kg/gün max 100 mg) kombinasyonunun tedavi sonu (erken dönem) ve tedaviden bir yıl sonra (geç dönem) etkinliği değerlendirildi.Bulgular:Her üç hastamızda da ne tedavinin tamamlandığı altıncı ayda, ne de yaklaşık bir yıllık takip dönemi sonunda HBeAg/anti HBe serokonversiyonu gelişmedi. İki hastada tedavi sonunda negatifleşen HBV DNA, takiplerde yeniden pozitifleşerek devam etti.Sonuç: Çalışma gurubunu oluşturan üç KHB enfeksiyonlu olguda timozin 1 alfa ve lamivudin kombinasyonunun etkin olmadığı gözlendi.
Aim: Combination therapy with different classes of agents in chronic hepatitis B (CHB) infection has recently been emphasized to be investigated for their efficacious in most recent studies. Up to date, the best treatment modality is unknown in patients with CHB infection.Material and Method: Results of treatment with thymosine 1 alpha (0.9 mg/m2 twice a week sc) in combination with lamivudine (4 mg/kg/day max 100 mg) in three patients with chronic hepatitis B infection who did not respond to interferon alpha treatment regimen were investigated at the end of therapy (early response) and one year later (delayed response). Results: HBeAg/antiHBe seroconversion did not occur neither at the end of the six months of the treatment period nor after one year following the discontinuation of this combination therapy. Two patients had HBV DNA clearance at the end of the treatment, but have relapsed during the follow-up period. Conclusion: Combination therapy of thymosin 1 alpha and lamivudine was not found to be effective in three patients with CHB infection.
Aim: Combination therapy with different classes of agents in chronic hepatitis B (CHB) infection has recently been emphasized to be investigated for their efficacious in most recent studies. Up to date, the best treatment modality is unknown in patients with CHB infection.Material and Method: Results of treatment with thymosine 1 alpha (0.9 mg/m2 twice a week sc) in combination with lamivudine (4 mg/kg/day max 100 mg) in three patients with chronic hepatitis B infection who did not respond to interferon alpha treatment regimen were investigated at the end of therapy (early response) and one year later (delayed response). Results: HBeAg/antiHBe seroconversion did not occur neither at the end of the six months of the treatment period nor after one year following the discontinuation of this combination therapy. Two patients had HBV DNA clearance at the end of the treatment, but have relapsed during the follow-up period. Conclusion: Combination therapy of thymosin 1 alpha and lamivudine was not found to be effective in three patients with CHB infection.
Açıklama
Anahtar Kelimeler
Kronik hepatit B, Kombinasyon tedavi, Lamivudin, Timozin 1 alfa, Chronic hepatitis B, Combination therapy, Lamivudine, Thymosin 1 alpha
Kaynak
Türkiye Klinikleri Gastroenterohepatoloji Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
14
Sayı
1
Künye
Dikici, B., Boşnak, M., Boşnak, V., Dağlı, A. ve Haspolat, Y. K. (2003). Kronik hepatit B enfeksiyonunda timozin 1 alfa ve lamivudin kombinasyonu; 3 vakalık klinik deneyim. Türkiye Klinikleri Gastroenterohepatoloji Dergisi, 14(1), 32-36.
